Macrophage infiltration contributes to the pathogenesis of Type 2 diabetes. Mesenchymal stem cells (MSCs) possess immunomodulatory properties, making them an ideal candidate for therapeutic intervention. This study investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease. Materials & methods: Monocytes from control (n = 4) and Type 2 diabetic patients with end-stage renal disease (n = 5) were assessed using flow cytometry and microarray profiling, following 48 h of co-culture with MSCs. Results: Control subjects had a greater proportion of CD14 ++ CD16 -monocytes while diabetic patients had a higher proportion of CD14 ++ CD16 + and CD14 + CD16 ++ monocytes. MSCs promoted the proliferation of monocytes isolated from diabetic patients, reduced HLA-DR expression in both groups and promoted the expression of anti-inflammatory genes. Conclusion: MSC-derived factors alter the polarization of monocytes isolated from healthy and diabetic subjects toward an M2 phenotype.
Diabetic nephropathy (DN), a progressive kidney disease that results from enduring diabetes, is the leading cause of end-stage renal disease (ESRD) worldwide [1] . It is characterized by the accumulation of extracellular matrix and eventual glomerular and interstitial fibrosis, leading to declining renal function [2] . Chronic inflammation is a key factor promoting the development and progression of DN. The infiltration of monocytes and monocyte-derived macrophages is a hallmark of diabetic kidney disease, and the number of macrophages correlates with declining renal function in both humans and mice [3, 4] .
Monocytes show considerable heterogeneity in both phenotype and function [5] . The classification of human peripheral blood monocytes is centered on the expression of the LPS co-receptor, CD14 and the Fcϒ receptor III, CD16 [6] . Three [6] . Classical CD14 ++ CD16 -monocytes traffic to the site of inflammation via a CCR2-dependent mechanism during the early stages of inflammation where they exhibit functions related to a typical inflammatory response, such as phagocytosis and reactive oxygen species (ROS) production [5, 7] . By contrast, nonclassical CD14 + CD16 ++ monocytes predominantly patrol blood vessel walls and are believed to contribute to resident macrophage populations [8] . These cells also accumulate in a variety of chronic inflammatory diseases where they are recruited at a later stage of the inflammatory response via a CX3CR1-dependent pathway [5, 9] . The third subset, CD14 ++ CD16 + , is believed to be an intermediate phenotype between the classical and nonclassical subsets [6] . Importantly, although functionally and phenotypically distinct monocyte subsets exist, these subsets may denote the same cell at different stages of maturation. Supporting evidence confirms that classical CD14 ++ CD16 -monocytes ++ nonclassical subset, characterized by the downregulation of CD14 and CCR2 expression and the upregulation of CD16 and CX3CR1 [10] .
Current therapeutic approaches have been able to reduce proteinuria in patients with DN, but have shown limited success in attenuating disease progression. Mesenchymal stem (stromal) cells (MSCs) have been used in several clinical trials including kidney transplantation, renal allograft rejection and Type 2 diabetes (T2D), demonstrating promising results with no adverse side effects [11] [12] [13] . Preclinical studies show that administered MSCs home to sites of injury where they ameliorate renal injury and accelerate repair through paracrine and/or endocrine mechanisms. It has been well documented that MSCs have remarkable immunomodulatory abilities, capable of altering dendritic cell phenotype and function, and macrophage phenotype and function [14, 15] .
Despite the interest in MSC-based approaches for the treatment of human kidney injury, there is limited information on the effects that MSCs have on circulating human monocytes, the progenitors of dendritic cells and macrophages, particularly under chronic inflammatory conditions. This study investigated the effects of human bone marrow-derived MSCs on human monocytes isolated from healthy (control) subjects and Type 2 diabetic patients with ESRD.
Materials & methods

Study population
Blood was obtained from five Type 2 diabetic patients with ESRD due to their diabetes. All patients received regular, three-times per week, hemodialysis at Monash Medical Centre using polysulphone high-flux dialyzers. All anticoagulation for dialysis was with low-molecular-weight heparin (enoxaparin). Control blood was obtained from four donors from the Australian Red Cross Blood Service. Donor details are summarized in 
Monocyte purification
Peripheral blood mononuclear cells (PBMCs) were harvested from whole blood using Ficoll-Paque PLUS (GE Healthcare Life Sciences, Uppsala, Sweden) according to the manufacturer's guidelines. CD14 + monocytes were then sorted from the PBMCs using human anti-CD14 conjugated microbeads (Miltenyi Biotec, CA, USA), on a QuadroMACS (Miltenyi Biotec) separator. The purity of the CD14 + sorted cells was greater than 90% when confirmed by flow cytometry.
Flow cytometry
Immunophenotypic analysis of monocytes on day 0 and 2 by flow cytometry was performed using the following fluorochrome-conjugated anti-human antibodies: CD45-FITC, CD14-APC, CD16-eFluor ® 450 and HLA-DR-PE. All antibodies were purchased from eBioscience, Inc. (CA, USA). Cell population data were acquired using an FACSCanto II flow cytometer (BD Biosciences, CA, USA) with the FACS Diva acquisition software (BD Biosciences) and analyzed using FlowLogic FCS analysis software (Inivai Technologies, Melbourne, Australia).
Monocyte & MSC co-culture
Human bone marrow-derived MSCs purchased from the Tulane Centre for Stem Cell Research and Regenerative Medicine (Tulane University, LA, USA) were cultured and characterized as previously described [15] . For co-culture experiments, 3 × 10 5
CD14
+ monocytes were plated in six-well plates and 3 × 10 5 MSCs were plated indirectly on a 0.4 μm pore size Transwell (Millipore Corporation, MA, USA; Figure 1 ). Cells were co-cultured for 48 h in RPMI 1640 medium supplemented with 10% fetal bovine serum (Sigma-Aldrich, MO, USA), 1% l-glutamine and 1% penicillin-streptomycin (Gibco ® , NY, USA). Monocytes were visualized on an Olympus IX81 microscope and images captured with an Olympus IX2-UCB camera.
RNA isolation & microarray analysis
RNA was extracted using the RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer's guidelines. Any contaminating DNA was removed by using 50U DNase I (Qiagen). RNA quantity was measured using a Nanodrop ND 1000 spectrophotometer (Rockland, DE, USA), quality was determined with an Agilent 2100 electrophoresis bioanalyzer (Agilent, CA, USA) and an RNA integrity number threshold of ≥0.8 was used for all samples. Samples (5 ng RNA per sample) were prepared using an Ovation Pico WTA system V2 (NuGEN Technologies, Inc., Bemmel, The Netherlands) and Encore Biotin Module V2 (NuGEN Technologies, Inc.). 5μg of biotin-labeled fragmented cDNA was hybridized to an Affymetrix GeneChip ® Human Gene 2.0 ST array (Affymetrix, CA, USA). Data were background corrected, log 2 transformed and quantile normalized using the bioconductor packages for gene-expression profiling in R. A linear model was then fitted to the normalized data and differential gene expression was when samples had a log 2 -fold change of <-0.75 and >0.75. False discovery rate (FDR) correction was performed on the p-values according to methods described by Benjamini and Hochberg using the limma bioconductor package. An FDR p-value of ≤0.05 was considered statistically significant. The list of differentially expressed genes was then subjected to pathway analysis using Ingenuity Pathway Analysis software (Ingenuity Systems, CA, USA). Microarray data can be visualized at the stemformatic website [16] .
Statistical analysis
All statistical analyses, except for the microarray analysis, were performed using GraphPad Prism software version 5.0 (GraphPad Software, Inc., CA, USA). Comparisons between two groups were made with a Student's t-test (unpaired, two-tailed). All data are expressed as means ± standard deviation (SD). A p-value of <0.05 was considered statically significant.
Results
The proportions of blood monocyte subsets are altered in Type 2 diabetic patients with ESRD
To understand the impact of T2D on blood monocytes, flow cytometry was used to assess and compare the phenotypes and relative proportions of freshly purified monocytes from control and diabetic subjects based on the expression of the monocyte markers CD14 and CD16. The baseline clinical parameters of the study participants are shown in Table 1 . All diabetic subjects had T2D with ESRD and were receiving hemodialysis at the time of blood collection. Representative dot plots 
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Upper compartment Lower compartment Within the monocyte pool, there were a significantly greater proportion of classical monocytes from control subjects, compared with those from Type 2 diabetic patients ( Figure 2B ; T2D: 56.3 ± 11.0% vs control: 73.9 ± 7.2%; p < 0.05). By contrast, the Type 2 diabetic patients had a higher proportion of intermediate ( Figure 2C ; T2D: 32.2 ± 8.0% vs control: 19.2 ± 6.7%; p < 0.05) and nonclassical ( Figure 2D ; T2D: 7.5 ± 2.5 vs control: 2.8 ± 1.1%; p < 0.05) monocytes, compared with the control subjects. Purified monocytes were also cytospun and subjected to Giemsa staining. Representative bright field images of monocytes from both subject groups (included in the dot plots in Figure 2A ) confirmed normal monocyte morphology. These data identified a shift in the proportions of the different monocyte subsets in patients with T2D-mediated ESRD.
MSCs alter the maturation state of monocytes
MSCs can exert their immunomodulatory and regenerative effects through the release of soluble factors. In order to test this, monocytes from healthy control subjects and Type 2 diabetic patients were co-cultured with MSCs for 48 h using a Transwell system. MSCs promoted the expansion of the T2D monocytes (T2D monocytes alone: 6.0 × 10 4 ± 2.2 × 10 4 vs T2D monocytes + MSCs: 19.4 × 10 4 ± 8.0 4 ; p < 0.01), but this effect was not seen in the control monocytes co-cultured under the same conditions ( Figure 3A & B). Both the control and T2D monocytes displayed a more uniform Figure 3C ). Co-culture of monocytes with MSCs caused a significant upregulation of CD14 and CD16 expression on the Type 2 diabetic patient monocytes, as depicted by an increased mean fluorescence intensity (MFI) of the CD14 ( Figure 4D ; T2D monocytes alone: 2.3 × 10 4 ± 1.5 × 10 3 vs T2D monocytes + MSCs: 3.3 × 10 4 ± 3.3 × 10 3 ; p < 0.001) and CD16 ( Figure 4E ; T2D monocytes alone: 2.5 × 10 3 ± 59.1 vs T2D monocytes + MSCs: 3.0 × 10 3 ± 521.5; p < 0.05) parameters. This trend was also observed in the control group ( Figure 4A & B) . By contrast, HLA-DR expression on co-cultured monocytes was significantly lower in both control ( Figure 4C ; 1.2 × 10 4 ± 4.8 × 10 3 vs 4.9 × 10 3 ± 1.1 × 10 3 ; p < 0.05) and T2D ( Figure 4F ; 1.4 × 10 4 ± 7.0 × 10 3 vs 5.6 × 10 3 ± 2.6 × 10 3 ; p < 0.05) monocytes. These results indicate that the MSCs promoted the maturation of monocytes without concurrent expression of class II antigen presentation complexes. We predicted the resulting macrophages would have a less inflammatory phenotype, so microarray expression profiling was undertaken to assess other changes in inflammatory signaling pathways resulting from MSC co-culture.
Monocytes co-cultured with MSCs have distinct gene-expression profiles
Monocytes from control subjects and patients with T2D and ESRD were profiled before and after MSC co-culture. Principal component analysis (PCA) revealed that the MSC treatment was the biggest driver of expression variation between the samples ( Figure 5A ). Following co-culture with MSCs, a total of 324 genes were differentially expressed (pairwise analysis, threshold of >twofold and adjusted p-value < 0.05), with 212 genes significantly upregulated (red) and 112 genes significantly downregulated (green) in both MSC-treated monocyte groups, compared with the monocyte alone groups ( Figure 5B & Supplementary Tables 1 & 2) .
Hierarchical clustering and heatmap visualization of the differentially expressed genes further demonstrated altered maturation profiles of the MSC cocultured monocytes, with downregulation (blue) of the nonclassical monocyte markers ITGAL and SPN and the upregulation (red) of the classical monocyte markers FCGR2A and FCGR2B (both associated with CD64), CD163, CD93, CD38, CLEC4D, HIF1A and FPR1 ( Figure 5C ). MSC treatment also significantly upregulated factors associated with a reparative macrophage phenotype, including the cytokines IL-10, IGF1, CCL2 and VEGF-A; membrane receptors MRC1, CD163, CD163L1, CD226, CD93, LILRB1 and PTGER2 (also known as EP2); and enzymes MMP9, MMP19, F13A1, SERPINB2 and PTGS2 (also known as COX2; Figure 5D ). These data were consistent with the changed patterns of CD14, CD16 and MHC class II protein expression detected previously (Figures 2-4) , demonstrating that the alterations in monocyte phenotype are the result of an altered transcriptional program.
The top ten canonical signaling pathways significantly over-represented in the MSC-treated monocytes ( Figure 6 & Table 2 ) shared several common genes indicative of cell maturation including Fcϒ receptors (FCGR1B, FCGR2A, FCGR2B and  FCGR3A) , MHC class II molecules (HLA-DMB and HLA-DQB1) and adhesion molecules (ITGAL, ITGAX, ITGA9 and ICAM1). Interestingly, the MHC class II molecules and many of the adhesion molecules were in fact downregulated by the MSC treatment (Supplementary Table 3 ). Genes commonly associated with an inflammatory macrophage phenotype were also downregulated, including APOE, APOC1, LPL and PPARG (Supplementary Table 3 ). IPA software was used to generate network hubs showing the common differentially expressed genes involved within the top ten signaling pathways (see Supplementary Figures 1 & 2) , and these networks were dominated by the reparative factors IL-10, IGF1, MMP9 and VEGF (Supplementary Figure 1) along with the classical monocyte and M2 macrophage associated phagocytic receptors FCGR1B, FCGR2A, FCGR2B and CD163 (Supplementary Figure 2) . Altogether, these results demonstrate that MSCs alter the maturation of monocytes toward a reparative macrophage phenotype.
Discussion
The current study explored the ability of MSCs to alter the phenotype of monocytes isolated from control and Type 2 diabetic subjects. We demonstrate that Type 2 diabetic patients displayed significantly higher proportions of the intermediate and nonclassical monocyte subsets contrasted to a higher proportion of circulating classical monocytes observed in control subjects. Although the nonclassical monocytes only constitute a minor subset, which is responsible for vessel patrolling during homeostasis, in a chronic inflammatory environment the CD14 + CD16 ++ subset accumulate and can contribute to the pathogenesis of disease [9] . Our findings correlate with other studies reporting increased numbers of circulating monocytes in T2D which display a pro-inflammatory profile and secrete the pro-inflammatory cytokines IL-6, IL-8, TNF-α and IL-1β [17] [18] [19] . In rodents, it has been demonstrated that these pro-inflammatory cytokines induce insulin resistance and that blocking these cytokines reverses this phenomenon [20] [21] [22] . Furthermore, monocytes from diabetic patients have demon- Mesenchymal stem cells alter the gene profile of monocytes Research Article strated impaired functionality, involving chemotaxis and phagocytosis [23, 24] .
The present study provides evidence that soluble factors produced by MSCs promoted the growth of monocytes in vitro in the disease group, and upregulated CD14 and CD16 expression, with a concomitant reduction in HLA-DR expression on both T2D and control monocytes. The immunomodulatory properties of MSCs have been reported to be more profound in an inflammatory environment compared with steady-state conditions, whereby the MSCs' immunosuppressive properties are primed by inflammatory stimuli [25, 26] . This was consistent with our own observations of more pronounced immunomodulatory effects of MSCs following co-culture with T2D monocytes. Our finding that MSCs have the capacity to modulate monocyte phenotype, is in accordance with other studies that have demonstrated MSC immunomodulatory abilities [27, 28] . Rocher et al. [27] [28] revealed that MSCs decreased the expression of HLA-DR and increased CD14 expression on monocytes in nonactivated and alloantigen-activated PBMC cultures. These cells also had increased CD206 expression, a marker associated with an anti-inflammatory M2 macrophage phenotype. Furthermore, these findings could be replicated using a Transwell co-culture system or the MSC-conditioned medium alone, indicating the effects were mediated by the MSC-derived soluble factors [28] . However, the precise mechanisms in which these MSC-derived soluble factors modulate monocyte phenotype remain to be fully elucidated.
Manipulating monocyte phenotype in order to reduce inflammation and subsequently insulin resistance could be a promising therapeutic option for Type 2 diabetic patients. Macrophage-derived IL-10 can inhibit the pathological effects of TNF-α-induced insulin resistance in adipocytes [29] . In an experimental model of Type 2 diabetes, the reduction of pro-inflammatory cytokines along with the enhancement of a reparative macrophage phenotype resulted in improved insulin signaling and glycemic control [30] . Fadini et al. [31] 
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Control monocytes + MSCs The present study demonstrated that MSCs upregulate several genes associated with an M2 macrophage phenotype, including the cytokines IL-10, IGF-1 and VEGF, known for their potent anti-inflammatory and regenerative abilities, and have the capacity to protect against diabetes in both mice and humans [32] [33] [34] .
Others have shown that IGF-1 administration can improve glycemic control in Type 2 diabetic patients by enhancing insulin sensitivity and reducing hyperglycemia and HbA1c [35] [36] [37] . Furthermore, macrophages expressing IGF-1 and IL-10 have both been shown to dampen inflammation and promote extracellular matrix remodeling and repair of damaged kidneys [38, 39] . During the early stages of diabetic nephropathy, elevated expression of VEGF is present within the kidney. However, as the disease advances, VEGF expression and activity declines [40, 41] . In humans, Tumlin et al. [42] demonstrated that in patients with advanced DN, a reduction in proteinuria and stabilization of renal function correlated with increased levels of urinary VEGF.
The present study demonstrated that MSCs upregulated several scavenger receptor genes, which are key players mediating the remodeling functions of macrophages following tissue damage. An increase in MMP-9 and MMP-19 was also observed, which in the kidney also contributes to extracellular matrix degradation and the attenuation of fibrosis [15, 43] . In addition, we observed an upregulation of the PTGER2-IL-10 signaling pathway in the MSC-treated monocytes regardless of whether the monocytes were from diabetic patients or healthy controls. MSCs enhanced PTGER2 gene expression in the monocytes. It has been demonstrated that MSCs secrete PGE 2 , which acts via the EP 2 receptor on monocytes, encoded by PTGER2. This secreted prostaglandin induces IL-10 production, resulting in immunosuppression [28, 44] . Additionally, PTGS2, which also induces the production of PGE 2 , was upregulated in the MSC-treated monocytes. Recent studies have shown that it is the MSC-derived PGE 2 that induces macrophage polarization toward a reparative phenotype [45] [46] [47] . However, this effect is lost as a result of PGE 2 ablation or blocking of the PGE 2 receptors, EP2 or EP4 [45, 47] . Therefore our results suggest that a major factor that promotes the MSC modulation of monocyte phenotype is IL-10.
MSCs may be capable of improving β-cell function and consequently insulin sensitivity, ameliorating hyperglycemia and glomerulosclerosis leading to significantly improved renal function in Type 1 and 2 diabetic rodents [48] [49] [50] [51] . In a Phase I clinical trial, three intravenous infusions of MSCs administered 1 month apart, to patients with T2D diabetes, reduced blood glucose levels and Hb1Ac, increased C-peptide and insulin secretion, indicative of an improvement in β-cell function and improved renal function [12] . Together, these studies highlight the ability of MSCs to target the many facets of this multifactorial disease. Their capability to reduce fibrosis, remodel/repair the damaged kidney and improve renal function, make MSCs a prime candidate to treat many forms of kidney damage. The additional immunosuppressive properties, which can dampen the inflammatory environment resulting in a downstream improvement in glycemic control, make them an ideal therapy for Type 2 diabetic patients.
Conclusion
In summary, we report that monocytes from Type 2 diabetic patients show a different phenotype compared with control cells, based on CD14 and CD16 expression. The inflammatory monocyte populations from Type 2 diabetic patients could be either perpetuating the underlying inflammation, or may provide an indicator of disease state. Nonetheless, these data provide a useful benchmark for which to assess potential treatments for T2D and DN. In this regard, manipulating monocyte phenotype and the pro-inflammatory state of T2D patients with the use of MSCs could serve as a useful tool for the development of a novel therapeutic option for patients with T2D.
Future perspective
These findings provide novel insight into the feasibility of administering MSCs to alter the profile of inflammatory monocytes and macrophages in patients with diabetes. MSCs may therefore have the potential to be harnessed for cell-based therapies to reduce the progression of DN in a setting of ESRD. The recruitment of inflammatory monocytes plays an important role in disease progression. Modulation of these cells, with the use of MSCs, is a potential therapeutic approach.
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Executive summary
Monocyte subsets
• Control subjects had a significantly greater proportion of CD14 ++ CD16 -classical monocytes compared with diabetic patients. By contrast, the diabetic patients had a higher proportion of CD14 ++ CD16 + intermediate and CD14
+ CD16 ++ nonclassical monocytes.
Mesenchymal stem cells alter the maturation state of monocytes
• Mesenchymal stem cells (MSCs) treatment impaired the differentiation of monocytes toward a pro-inflammatory nonclassical phenotype.
MSCs alter the maturation state of monocytes
• Principal component analysis revealed that MSC-treated monocytes clustered separately from the untreated monocytes.
• MSC co-culture promoted expression of anti-inflammatory genes consistent with an M2-like macrophage phenotype.
Limitations of the study
• Control patient samples would be optimally age-matched to Type 2 diabetic subjects.
• Protein validation of the key genes involved would provide valuable insight into the mechanism driving MSC modulation of monocyte phenotype.
